Interleukin-20 receptor complex (IL-20R complex)

The Interleukin-20 receptor complex is a heterodimeric cell-surface receptor composed primarily of an alpha subunit (IL-20 receptor alpha, IL20RA) and a beta subunit (IL-20 receptor beta, IL20RB)[2][6]. There are two main forms: the type I complex (IL-20RA/IL-20RB), which binds interleukin-19 (IL-19), interleukin-20 (IL-20), and interleukin-24 (IL-24), and the type II complex (IL-22RA1/IL-20RB), which binds IL-20 and IL-24 but not IL-19[1][4][5][6]. The receptor transduces signals via the JAK-STAT pathway, primarily activating STAT3, leading to transcription of target genes involved in inflammation, epithelial defense, and tissue repair[2][3][4][5]. The complex is found predominantly in epithelial tissues such as skin, lungs, gut, and also in immune cells[2][4][5]. Dysregulated signaling through the IL-20 receptor complex is implicated in several inflammatory and autoimmune diseases, including psoriasis, rheumatoid arthritis, and atherosclerosis[1][2][4][5]. Key Pathway: IL-20 family cytokines bind to these receptor complexes to activate the JAK-STAT pathway, mediating both pro- and anti-inflammatory responses depending on the context. Antagonism of this complex is being investigated for its therapeutic potential in chronic inflammatory diseases[1][4][5].

Other names

IL-20 receptortype I IL-20 receptor (IL-20RA/IL-20RB)type II IL-20 receptor (IL-22RA1/IL-20RB)IL-20 receptor complexIL-20R complex

Blockade of cytokine binding (e.g., anti-IL-20 monoclonal antibodies prevent ligand-receptor interaction) - Inhibition of JAK/STAT signaling pathway downstream of receptor activation